Latest Earnings Results: Q3 '26
Estimated EPS
$2.09
Reported EPS
$2.49
Surprise
+19.4%
Estimated Rev
$17.33B
Reported Rev
$18.09B
Surprise
+4.35%
• Reported GAAP EPS of $2.49 down -3.49% YoY • Reported revenue of $18.09B up 4.68% YoY • Merck & Co. raised and narrowed full-year 2026 sales outlook to $66.8B to $67.3B and non-GAAP EPS outlook to $2.77 to $2.82, including one-time SciBrunch charge.
Bullish Takeaway
Merck & Co. recorded growth in KEYTRUDA/KEYTRUDA QLEX and WINREVAIR sales, while Phase 3 INTerpath-001 results showed intismeran plus KEYTRUDA reduced recurrence-or-death risk by 42% versus KEYTRUDA alone.
Bearish Takeaway
Merck & Co. reported lower GAAP gross margin and non-GAAP EPS year over year, alongside JANUVIA/JANUMET sales declines tied to generic competition following loss of U.S. market exclusivity.
Generated by Stocktwits using AI and company-reported earnings data for Q3 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q4 '26 | $1.80 | -- | -- | N/A |
Q3 '26 | $2.09 | $2.49 | 19.40% | BEAT |
Q2 '26 | -$0.27 | -$0.13 | 51.42% | BEAT |
Q1 '26 | -$1.47 | -$1.28 | 13.15% | BEAT |
Q4 '25 | $2.01 | $2.04 | 1.43% | BEAT |